Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, announced that it has entered into a strategic collaboration agreement with Genentech, a member of the Roche Group, to discover, develop and commercialize novel Bicycle®-based immuno-oncology therapies.
Bicycle Therapeutics is developing a brand new class of small, chemically synthesized medicines called Bicycles.
B900 Babraham Research Campus Babraham
Post Code: CB22 3AT
Country: United Kingdom
Membership Type: Corporate 21-50